登录
 机构网站
  1. 首页
  2. 情报产品
  3. 快讯详情

《European Heart J，5月10日，Circulating plasma concentrations of angiotensin-converting enzyme 2 in men and women with heart failure and effects of renin–angiotensin–aldosterone inhibitors》

  • 来源专题：COVID-19科研动态监测
  • 编译者： xuwenwhlib
  • 发布时间：2020-05-11

  • Circulating plasma concentrations of angiotensin-converting enzyme 2 in men and women with heart failure and effects of renin–angiotensin–aldosterone inhibitors

    Iziah E Sama, Alice Ravera, Bernadet T Santema, Harry van Goor, Jozine M ter Maaten, John G F Cleland, Michiel Rienstra, Alex W Friedrich, Nilesh J Samani, Leong L Ng ... Show more

    European Heart Journal, ehaa373, https://doi.org/10.1093/eurheartj/ehaa373

    Abstract

    Aims

    The current pandemic coronavirus SARS-CoV-2 infects a wide age group but predominantly elderly individuals, especially men and those with cardiovascular disease. Recent reports suggest an association with use of renin–angiotensin–aldosterone system (RAAS) inhibitors. Angiotensin-converting enzyme 2 (ACE2) is a functional receptor for coronaviruses. Higher ACE2 concentrations might lead to increased vulnerability to SARS-CoV-2 in patients on RAAS inhibitors.

    Methods

    We measured ACE2 concentrations in 1485 men and 537 women with heart failure (index cohort). Results were validated in 1123 men and 575 women (validation cohort).

  • 原文来源：https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehaa373/5834647?searchresult=1
19浏览量
原文链接
相关报告

  • 《European Heart J，3月20日，SARS-CoV2: should inhibitors of the renin–angiotensin system be withdrawn in patients with COVID-19》
    • 来源专题：COVID-19科研动态监测
    • 编译者：zhangmin
    • 发布时间：2020-03-23
    • SARS-CoV2: should inhibitors of the renin–angiotensin system be withdrawn in patients with COVID-19? Gabriela M Kuster, Otmar Pfister, Thilo Burkard, Qian Zhou, Raphael Twerenbold, Philip Haaf, Andreas F Widmer, Stefan Osswald European Heart Journal, ehaa235, https://doi.org/10.1093/eurheartj/ehaa235 Published: 20 March 2020 In a rapid response published online by the British Medical Journal, Sommerstein and Gräni1 pushed forward the hypothesis that angiotensin-converting enzyme (ACE) inhibitors (ACE-Is) could act as a potential risk factor for fatal Corona virus disease 2019 (COVID-19) by up-regulating ACE2. This notion was quickly picked up by the lay press and sparked concerns among physicians and patients regarding the intake of inhibitors of the renin–angiotensin–aldosterone system (RAAS) by severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) infected individuals.1 In this article, we try to shed light on what is known and unknown regarding the RAAS and SARS-CoV2 interaction.
    77浏览量
    原文链接

  • 《NEJM，5月1日，Renin–Angiotensin–Aldosterone System Inhibitors and Risk of Covid-19》
    • 来源专题：COVID-19科研动态监测
    • 编译者：zhangmin
    • 发布时间：2020-05-02
    • Renin–Angiotensin–Aldosterone System Inhibitors and Risk of Covid-19 List of authors. Harmony R. Reynolds, M.D., Samrachana Adhikari, Ph.D., Claudia Pulgarin, M.A., M.S., Andrea B. Troxel, Sc.D., Eduardo Iturrate, M.D., M.S.W., Stephen B. Johnson, Ph.D., Anaïs Hausvater, M.D., Jonathan D. Newman, M.D., M.P.H., Jeffrey S. Berger, M.D., Sripal Bangalore, M.D., Stuart D. Katz, M.D., Glenn I. Fishman, M.D., et al. Abstract BACKGROUND There is concern about the potential of an increased risk related to medications that act on the renin–angiotensin–aldosterone system in patients exposed to coronavirus disease 2019 (Covid-19), because the viral receptor is angiotensin-converting enzyme 2 (ACE2). METHODS We assessed the relation between previous treatment with ACE inhibitors, angiotensin-receptor blockers, beta-blockers, calcium-channel blockers, or thiazide diuretics and the likelihood of a positive or negative result on Covid-19 testing as well as the likelihood of severe illness (defined as intensive care, mechanical ventilation, or death) among patients who tested positive. Using Bayesian methods, we compared outcomes in patients who had been treated with these medications and in untreated patients, overall and in those with hypertension, after propensity-score matching for receipt of each medication class. A difference of at least 10 percentage points was prespecified as a substantial difference.
    106浏览量
    原文链接